Brief: Rhythm Pharmaceuticals Announces First Patient Dosed In Phase 1 Trial Evaluating RM-718
25/03/2024 13:46
March 25 (Reuters) - Rhythm Pharmaceuticals Inc
RYTM.O :
* RHYTHM PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN
PHASE 1
TRIAL EVALUATING RM-718, A WEEKLY MC4R-SPECIFIC AGONIST
* RHYTHM PHARMACEUTICALS INC - THREE-PART STUDY TO EVALUATE
SAFETY, TOLERABILITY AND PHARMACOKINETICS NOW UNDERWAY
* RHYTHM PHARMACEUTICALS INC - RM-718 SHOWED POTENTIAL TO
REDUCE
BODY WEIGHT AND HYPERPHAGIA, NO HYPERPIGMENTATION OBSERVED IN
PRECLINICAL STUDIES
Source text for Eikon: ID:nGNX60wQfJ
Further company coverage: RYTM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rhythm Pharmaceuticals
See all newsBrief: Rhythm Pharmaceuticals Announces Appointment Of Manher (Aj) Joshi As Chief Medical Officer
Rhythm's drug shows promise for brain tumor-related weight condition in small study (updated)
Rhythm Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition
Rhythm Pharmaceuticals Q2 net loss narrows on US launch demand